US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5156840A
(en)
|
1982-03-09 |
1992-10-20 |
Cytogen Corporation |
Amine-containing porphyrin derivatives
|
US5057313A
(en)
|
1986-02-25 |
1991-10-15 |
The Center For Molecular Medicine And Immunology |
Diagnostic and therapeutic antibody conjugates
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
JPH0395163A
(ja)
|
1989-09-08 |
1991-04-19 |
Daicel Chem Ind Ltd |
2.2.4.4.6―ペンタメチル―2.3.4.5―テトラヒドロピリミジンの製造法
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
ATE207080T1
(de)
|
1991-11-25 |
2001-11-15 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
EP0859841B1
(en)
|
1995-08-18 |
2002-06-19 |
MorphoSys AG |
Protein/(poly)peptide libraries
|
US20020077461A1
(en)
|
1996-04-24 |
2002-06-20 |
Soren Bjorn |
Pharmaceutical formulation
|
TR200201506T2
(tr)
|
1999-09-17 |
2002-10-21 |
Abbott Gmbh & Co. Kg |
Terapötik maddeler olarak kinaz inhibitörleri
|
US20040089753A1
(en)
|
2000-06-28 |
2004-05-13 |
Holland Simon Joseph |
Wet milling process
|
HUP0304093A3
(en)
|
2001-04-06 |
2008-08-28 |
Wyeth Corp |
Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them
|
GB0221697D0
(en)
|
2002-09-18 |
2002-10-30 |
Unilever Plc |
Novel compouds and their uses
|
AU2003272175A1
(en)
|
2002-10-21 |
2004-05-04 |
Aprea Ab |
Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス,インコーポレーテッド |
変異型Fc領域を含む抗体の同定および作製ならびにその利用法
|
WO2004065416A2
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
WO2004072266A2
(en)
|
2003-02-13 |
2004-08-26 |
Kalobios Inc. |
Antibody affinity engineering by serial epitope-guided complementarity replacement
|
EP1974726B1
(en)
|
2003-03-26 |
2010-01-13 |
Egalet A/S |
Matrix compositions for controlled delivery of drug substances
|
ATE482235T1
(de)
|
2003-06-13 |
2010-10-15 |
Biogen Idec Inc |
Aglycosyl-anti-cd154 (cd40-ligand) antikörper und deren verwendungen
|
AU2004266159A1
(en)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
WO2005025515A2
(en)
|
2003-09-12 |
2005-03-24 |
California Institute Of Technology |
Proteasome pathway inhibitors and related methods
|
DK1740591T3
(da)
|
2004-04-02 |
2009-10-26 |
Osi Pharm Inc |
Heterobicykliske proteinkinaseinhibitorer substitueret med en 6,6-biocyclisk ring
|
UY28931A1
(es)
|
2004-06-03 |
2005-12-30 |
Bayer Pharmaceuticals Corp |
Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
|
TW200613306A
(en)
|
2004-07-20 |
2006-05-01 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
UY29177A1
(es)
|
2004-10-25 |
2006-05-31 |
Astex Therapeutics Ltd |
Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
|
JP2008520612A
(ja)
|
2004-11-24 |
2008-06-19 |
ノバルティス アクチエンゲゼルシャフト |
JAK阻害剤およびBcr−Abl、Flt−3、FAKまたはRAFキナーゼ阻害剤のうち少なくとも1個の組合せ
|
PT1951724E
(pt)
|
2005-11-17 |
2011-08-02 |
Osi Pharm Inc |
Inibidores mtor fundidos bicíclicos
|
KR101461680B1
(ko)
|
2005-12-02 |
2014-11-19 |
바이엘 헬스케어 엘엘씨 |
과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
|
PE20070855A1
(es)
|
2005-12-02 |
2007-10-14 |
Bayer Pharmaceuticals Corp |
Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
|
DK2455382T3
(da)
|
2005-12-13 |
2017-01-02 |
Incyte Holdings Corp |
Heteroaryl substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus kinase-inhibitorer
|
ES2562428T3
(es)
|
2005-12-15 |
2016-03-04 |
Rigel Pharmaceuticals, Inc. |
Inhibidores de cinasa y sus usos
|
TW200808805A
(en)
|
2006-04-12 |
2008-02-16 |
Vertex Pharma |
Tetrahydropteridines useful as inhibitors of protein kinases
|
SI2010528T1
(en)
|
2006-04-19 |
2018-02-28 |
Novartis Ag |
6-O-substituted benzoxazole and benzothiazole compounds and procedures for inhibiting CSF-1R signaling
|
WO2007125315A2
(en)
|
2006-04-25 |
2007-11-08 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
WO2008048375A1
(en)
|
2006-05-19 |
2008-04-24 |
Bayer Healthcare Ag |
Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
|
US8097630B2
(en)
|
2006-10-10 |
2012-01-17 |
Rigel Pharmaceuticals, Inc. |
Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors
|
MX2009006345A
(es)
|
2006-12-14 |
2009-06-23 |
Vertex Pharma |
Compuestos utiles como inhibidores de proteina cinasa.
|
US9650391B2
(en)
|
2006-12-29 |
2017-05-16 |
Rigel Pharmaceuticals Inc. |
N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors
|
US7872000B2
(en)
|
2006-12-29 |
2011-01-18 |
Rigel Pharmaceuticals, Inc. |
Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as Axl inhibitors
|
DK2078010T3
(da)
|
2006-12-29 |
2014-04-28 |
Rigel Pharmaceuticals Inc |
Polycyklisk heteroaryl-substituerede triazoler, der er anvendelige som axl-hæmmere
|
EP2114983B8
(en)
|
2007-02-07 |
2015-02-18 |
The Regents of the University of Colorado, A Body Corporate |
Axl tyrosine kinase inhibitors and methods of making and using the same
|
CA2680680A1
(en)
|
2007-03-29 |
2009-02-19 |
Panacea Biotec Limited |
Modified dosage forms of tacrolimus
|
RS51226B
(sr)
|
2007-06-12 |
2010-12-31 |
Concert Pharmaceuticals Inc. |
Derivati azapeptida kao inhibitori hiv proteaze
|
US8461149B2
(en)
|
2007-08-15 |
2013-06-11 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as protein kinase inhibitors
|
GB0719803D0
(en)
|
2007-10-10 |
2007-11-21 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
CA2703653A1
(en)
|
2007-10-25 |
2009-04-30 |
Astrazeneca Ab |
Pyridine and pyrazine derivatives -083
|
US7935693B2
(en)
|
2007-10-26 |
2011-05-03 |
Rigel Pharmaceuticals, Inc. |
Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as Axl inhibitors
|
CN101945867A
(zh)
|
2007-12-19 |
2011-01-12 |
安姆根有限公司 |
作为细胞周期抑制剂的稠合吡啶、嘧啶和三嗪化合物
|
AR070127A1
(es)
|
2008-01-11 |
2010-03-17 |
Novartis Ag |
Pirrolo - pirimidinas y pirrolo -piridinas
|
WO2009127417A1
(en)
|
2008-04-16 |
2009-10-22 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Quinoline derivatives as axl kinase inhibitors
|
TWI539953B
(zh)
|
2008-04-28 |
2016-07-01 |
瑞波若斯治療學公司 |
用於治療乳癌之組成物和方法
|
EP2356122B1
(en)
|
2008-06-23 |
2019-03-20 |
Vertex Pharmaceuticals Incorporated |
Protein kinase inhibitors
|
US8349838B2
(en)
|
2008-07-09 |
2013-01-08 |
Rigel Pharmaceuticals, Inc. |
Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors
|
PL2328888T3
(pl)
|
2008-07-09 |
2013-04-30 |
Rigel Pharmaceuticals Inc |
Triazole podstawione mostkowanym bicyklicznym heteroarylem użyteczne jako inhibitory AXL
|
WO2010014755A1
(en)
|
2008-07-29 |
2010-02-04 |
The Regents Of The University Of Colorado |
Methods and compounds for enhancing anti-cancer therapy
|
EP2158913A1
(en)
|
2008-08-25 |
2010-03-03 |
Ratiopharm GmbH |
Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
|
US20100075973A1
(en)
|
2008-08-28 |
2010-03-25 |
Takeda Pharmaceutical Company Limited |
Polo-like kinase inhibitors
|
ES2539620T3
(es)
|
2008-12-19 |
2015-07-02 |
Cephalon, Inc. |
Pirrolotriazina como inhibidor de ALK y de JAK2
|
WO2010090764A1
(en)
|
2009-02-09 |
2010-08-12 |
Supergen, Inc. |
Pyrrolopyrimidinyl axl kinase inhibitors
|
WO2010126960A1
(en)
|
2009-04-29 |
2010-11-04 |
Locus Pharmaceuticals, Inc. |
Pyrrolotriazine compounds
|
WO2011139273A1
(en)
|
2010-05-05 |
2011-11-10 |
Vertex Pharmaceuticals Incorporated |
4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors
|
NZ596479A
(en)
|
2009-05-22 |
2014-01-31 |
Incyte Corp |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
EP2845856A1
(en)
|
2009-06-29 |
2015-03-11 |
Incyte Corporation |
Pyrimidinones as PI3K inhibitors
|
US9249145B2
(en)
|
2009-09-01 |
2016-02-02 |
Incyte Holdings Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
BR112012006639A2
(pt)
|
2009-09-25 |
2015-09-08 |
Vertex Pharma |
métodos para preparar derivados de pirimidina úteis como inibidores de protéina quinase
|
EP2311809A1
(en)
|
2009-10-16 |
2011-04-20 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Quinolinyloxyphenylsulfonamides
|
US8604217B2
(en)
|
2009-11-12 |
2013-12-10 |
Selvita S.A. |
Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
|
US8680108B2
(en)
|
2009-12-18 |
2014-03-25 |
Incyte Corporation |
Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
|
SG183551A1
(en)
|
2010-03-10 |
2012-10-30 |
Incyte Corp |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
WO2011123493A1
(en)
|
2010-03-31 |
2011-10-06 |
Bristol-Myers Squibb Company |
Substituted pyrrolotriazines as protein kinase inhibitors
|
EP2423208A1
(en)
|
2010-08-28 |
2012-02-29 |
Lead Discovery Center GmbH |
Pharmaceutically active compounds as Axl inhibitors
|
CN103403010A
(zh)
|
2010-10-08 |
2013-11-20 |
依兰制药公司 |
Polo样激酶的抑制剂
|
ITRM20100537A1
(it)
|
2010-10-12 |
2012-04-12 |
Consiglio Nazionale Ricerche |
Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
|
UA113156C2
(xx)
|
2010-11-19 |
2016-12-26 |
|
Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
US9096600B2
(en)
|
2010-12-20 |
2015-08-04 |
Incyte Corporation |
N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
|
MX352844B
(es)
|
2011-02-28 |
2017-12-11 |
Calitor Sciences Llc |
Compuestos de quinolina sustituidos y metodos de uso.
|
US8623885B2
(en)
|
2011-03-23 |
2014-01-07 |
Amgen Inc. |
Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
|
EP2693881B1
(en)
|
2011-04-01 |
2019-09-04 |
University of Utah Research Foundation |
Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
|
AR086913A1
(es)
|
2011-06-14 |
2014-01-29 |
Novartis Ag |
4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
|
JP5876146B2
(ja)
|
2011-06-20 |
2016-03-02 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Jak阻害剤としてのアゼチジニルフェニル、ピリジル、またはピラジニルカルボキサミド誘導体
|
MX2013014315A
(es)
|
2011-07-01 |
2014-01-31 |
Bayer Pharma AG |
Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos.
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
BR112014004971B1
(pt)
|
2011-09-02 |
2021-02-09 |
Incyte Holdings Corporation |
compostos heterociclilaminas, sua composição farmacêutica e seus usos
|
EP3318284B1
(en)
|
2011-09-18 |
2022-01-26 |
Euro-Celtique S.A. |
Pharmaceutical composition comprising an hdac inhibitor and a cyclopolysaccharide
|
CN102408411B
(zh)
|
2011-09-19 |
2014-10-22 |
北京康辰药业股份有限公司 |
一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
|
US9273056B2
(en)
|
2011-10-03 |
2016-03-01 |
The University Of North Carolina At Chapel Hill |
Pyrrolopyrimidine compounds for the treatment of cancer
|
HUE033032T2
(hu)
|
2011-11-14 |
2017-11-28 |
Ignyta Inc |
Uracil-származékok mint AXL és c-MET kináz inhibitorok
|
EP2785700B1
(en)
|
2011-11-29 |
2016-03-09 |
Perosphere, Inc. |
Anticoagulant reversal agents
|
EP2788000B1
(en)
|
2011-12-06 |
2018-05-30 |
Merck Sharp & Dohme Corp. |
Pyrrolopyrimidines as janus kinase inhibitors
|
LT2810937T
(lt)
|
2012-01-31 |
2017-02-10 |
Daiichi Sankyo Company, Limited |
Piridono darinys
|
CA2865021C
(en)
|
2012-02-23 |
2020-06-30 |
Bayer Intellectual Property Gmbh |
Substituted benzothienyl-pyrrolotriazines and uses thereof
|
WO2013162061A1
(ja)
|
2012-04-26 |
2013-10-31 |
第一三共株式会社 |
二環性ピリミジン化合物
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
ES2889757T3
(es)
|
2012-09-06 |
2022-01-13 |
Plexxikon Inc |
Compuestos y procedimientos para la modulación de quinasas e indicaciones para estos
|
RU2015115631A
(ru)
|
2012-09-26 |
2016-11-20 |
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния |
Модулирование ire1
|
WO2014062774A1
(en)
|
2012-10-17 |
2014-04-24 |
The University Of North Carolina At Chapel Hill |
Pyrazolopyrimidine compounds for the treatment of cancer
|
EP2917221A1
(en)
|
2012-11-01 |
2015-09-16 |
Incyte Corporation |
Tricyclic fused thiophene derivatives as jak inhibitors
|
EP2922857B1
(en)
|
2012-11-20 |
2018-01-03 |
ProQinase GmbH |
Thioether derivatives as protein kinase inhibitors
|
WO2014109858A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
TW201522337A
(zh)
|
2013-03-12 |
2015-06-16 |
Arqule Inc |
經取代之三環吡唑並-嘧啶化合物類
|
TWI649308B
(zh)
|
2013-07-24 |
2019-02-01 |
小野藥品工業股份有限公司 |
喹啉衍生物
|
US9586967B2
(en)
|
2013-11-08 |
2017-03-07 |
Ono Pharmaceutical Co., Ltd. |
Pyrrolo pyrimidine derivative
|
CA2934989C
(en)
|
2014-02-03 |
2017-08-08 |
Cadila Healthcare Limited |
Novel heterocyclic compounds
|
GB201420285D0
(en)
|
2014-11-14 |
2014-12-31 |
Bergenbio As |
Process
|
EP3233829B1
(en)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
US9840503B2
(en)
|
2015-05-11 |
2017-12-12 |
Incyte Corporation |
Heterocyclic compounds and uses thereof
|
GEP20227419B
(en)
|
2015-07-30 |
2022-10-10 |
Macrogenics Inc |
Pd-1-binding molecules and methods of use thereof
|
WO2017027717A1
(en)
|
2015-08-12 |
2017-02-16 |
Incyte Corporation |
Bicyclic fused pyrimidine compounds as tam inhibitors
|
US10053465B2
(en)
|
2015-08-26 |
2018-08-21 |
Incyte Corporation |
Pyrrolopyrimidine derivatives as TAM inhibitors
|
US20180296561A1
(en)
|
2015-10-07 |
2018-10-18 |
The University Of North Carolina At Chapel Hill |
The Methods For Treatment Of Tumors
|
MX2018004516A
(es)
|
2015-10-13 |
2018-08-01 |
Nihon Nohyaku Co Ltd |
Compuesto heterociclico condensado con contenido de grupo oxima o su sal, insecticida agricola y horticola que comprende el compuesto y metodo para usar el insecticida.
|
US9695150B2
(en)
|
2015-11-14 |
2017-07-04 |
Calitor Sciences, Llc |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
WO2017083788A1
(en)
|
2015-11-14 |
2017-05-18 |
Sunshine Lake Pharma Co., Ltd. |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
SG11201808582RA
(en)
|
2016-03-28 |
2018-10-30 |
Incyte Corp |
Pyrrolotriazine compounds as tam inhibitors
|
SG11201809299QA
(en)
*
|
2016-04-22 |
2018-11-29 |
Incyte Corp |
Formulations of an lsd1 inhibitor
|
TW201803871A
(zh)
|
2016-06-24 |
2018-02-01 |
英塞特公司 |
作為PI3K-γ抑制劑之雜環化合物
|
JOP20170153A1
(ar)
|
2016-07-15 |
2019-01-30 |
Lilly Co Eli |
نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
|
IL308256A
(en)
|
2016-07-15 |
2024-01-01 |
Ionis Pharmaceuticals Inc |
Compounds and Methods for Modulating SMN2
|
JOP20190257A1
(ar)
|
2017-04-28 |
2019-10-28 |
Novartis Ag |
مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
|
JP2020535168A
(ja)
|
2017-09-27 |
2020-12-03 |
インサイト・コーポレイションIncyte Corporation |
Tam阻害剤として有用なピロロトリアジン誘導体の塩
|
EP3813800A1
(en)
|
2018-06-29 |
2021-05-05 |
Incyte Corporation |
Formulations of an axl/mer inhibitor
|
EP4114401A1
(en)
|
2020-03-06 |
2023-01-11 |
Incyte Corporation |
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
|